Olanzapine versus megestrol acetate in treating loss of appetite in patients with cancer undergoing chemotherapy

olanzapine versus megastrol acetate in treating loss of appetite in patients with cancer undergoing chemotherapy - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/08/072844

Enrollment

120

Registered

2024-08-21

Start date

Unknown

Completion date

Unknown

Last updated

2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C788- Secondary malignant neoplasm of other and unspecified digestive organs

Interventions

Intervention1: Olanzapine 2.5 mg once a day for 8 weeks: Olanzapine is found to more effective in improving appetite and is more cost-effective. Control Intervention1: Megestrol 40 MG ONCE A DAY FOR 8

Eligibility

Inclusion criteria

Inclusion criteria: All stage 3 and 4 GI and lung cancer patients

Exclusion criteria

Exclusion criteria: Cancer patient who are on longterm steroid pregnancy

Design outcomes

Primary

Measure	Time frame
To find out the effective agent that can prevent cachexia/anorexia associated with chemotherapyTimepoint: To find out the effective agent that can prevent cachexia/anorexia associated with chemotherapy	—

Secondary

Measure	Time frame
To determine whether olanzapine leads to a greater proportion of patients who report a 5% or greater weight gain from baseline compared to megestrol acetate. To compare change in cachexia/anorexia symptoms with olanzapine compared to megestrol acetate using the Functional Assessment of anorexia/cachexia treatment (FAACT)-Anorexia/Cachexia Subscale (A/CS)instrument Timepoint: 1 year	—

Countries

India

Contacts

Public ContactDr Anjali Murali

Amrita institute of medical science

anjalim@aims.amrita.edu8111964417

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026